The collaboration between Genisphere LLC, provider of the 3DNAA drug delivery platform, and the PDT is a complementary treatment option that can be added to surgery for removal of residual cancer. Photosensitizing drugs are administered to patients prior to surgery, and then activated by visible light after the tumor tissue is removed, to destroy cancerous cells left behind.
